National Cancer Institute; Notice of Closed Meeting, 40386-40387 [05-13813]

Download as PDF 40386 Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices 0871492, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/ 1–GB–12]; United States Patent No. 5,320,956, issued June 14, 1996, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–US–20]; United States Patent No. 5,525,337, issued June 11, 1996, entitled ‘‘Monoclonal Antibody Binding Cell Surface Antigen For Diagnosing Cancer’’ [E–195–1990/0–US–21]; United States Patent No. 5,817,313, issued October 6, 1998, entitled ‘‘Monoclonal Antibodies And Conjugates Thereof Useful For The Treatment Of Cancer’’ [E–195–1990/0– US–22]; PCT Patent Application No. PCT/US91/07227, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E– 195–1990/0–PCT–02]; Denmark Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E– 195–1990/0–DK–03]; United Kingdom Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/0–GB–04]; Austrian Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E– 195–1990/0–AT–05]; Belgium Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E– 195–1990/0–BE–06]; European Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E– 195–1990/0–EP–09]; French Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–FR–11]; German Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–DE–08]; Greece Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–GR–12]; Netherlands Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–NL–15]; Italian Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–IT–13]; Luxembourg Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–LU–14]; Spanish Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0-ES–10]; Sweden Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–SE–16]; Switzerland Patent No. 0554356, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–CH–07]; Australian Patent No. 648363, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–AU–17]; Canadian Patent No. 2093928, filed October 9, 1991, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–CA–18]; and Japanese Patent No. 2660241, filed October 9, 1991, entitled VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 ‘‘Monoclonal Antibody’’ [E–195–1990/ 0–JP–19] to Morphotek, Inc., which has offices in Exton, Pennsylvania. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of licensee’s MORAb–009 antibody for the treatment of mesothelin-expressing cancer. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 12, 2005 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jesse S. Kindra, J.D., M.S., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5559; Facsimile: (301) 402–0220; E-mail: kindraj@mail.nih.gov. SUPPLEMENTARY INFORMATION: The technology relates to CAK1, or ‘‘mesothelin’’, which is an antigen present on the cell surface in mesothelium and on many mesotheliomas and ovarian cancers. While the role of this differentiation antigen has not yet been determined, it is postulated that it may be implicated in adhesion and in the dissemination of mesotheliomas and of ovarian cancers. CAK1, therefore, is a potential target for monoclonal antibodies to be used in the diagnosis and treatment of these cancers. The gene for CAK1 has been cloned and sequenced, as embodied in the current technology. This technology, therefore, should provide a valuable research tool for use in the development of diagnostics and/or therapeutic agents toward mesotheliomas and ovarian cancers. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: July 1, 2005. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–13804 Filed 7–12–05; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Centers of Cancer Nanotechnology Excellence (CCNEs). Date: July 19–22, 2005. Time: 6 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Georgetown, 2101 Wisconsin Ave NW., Washington, DC 20007. Contact Person: Michael B. Small, PhD, Scientific Review Administrator, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8127, Bethesda, MD 20892–8328, 301–402–0996, smallm@mail.nih.gov. This notice is published less than 15 days prior to meeting due to scheduling conflicts. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) E:\FR\FM\13JYN1.SGM 13JYN1 Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices Dated: July 5, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–13813 Filed 7–12–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Lab Assessment of Tobacco Use Behavior & Exposure Toxins. Date: August 4, 2005. Time: 8 a.m. to 4 p.m. Agenda: To review and evaluate contract proposals. Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave, Bethesda, MD 20814. Contact Person: Joyce C. Pegues, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd. 7149, Bethesda, MD 20892, 301/594–1286, peguesj@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 5, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–13816 Filed 7–12–05; 8:45 am] BILLING CODE 4140–01–M VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Initial Review Group, Subcommittee E—Cancer Epidemiology, Prevention & Control. Date: August 11–12, 2005. Time: 8 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Mary C. Fletcher, PhD, Scientific Review Administrator, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Rm 8115, Bethesda, MD 20892, (301) 496–7413. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 5, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–13817 Filed 7–12–05; 8:45 am] 40387 amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. the grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel, MCMHD Community-Based Participatory Research & Outreach. Date: July 18–20, 2005. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Merlyn M. Rodrigues, PhD, MD, Director, Office of Extramural Activities, National Center On Minority Health, and Health Disparities, National Institute of Health, 6707 Democracy Blvd. Suite 800, Bethesda, MD 20894, (301) 402–1366, rodrigm1@mail.nih.gov. Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel, Project EXPORT— Establishing Exploratory Centers. Date: July 24–26, 2005. Time: 5 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Lorrita Watson, PhD, National Center on Minority Health and Health Disparities, National Institutes of Health, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20892–5465, 301–594–7784, watsonl@ncmhd.nih.gov. Dated: June 30, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–13811 Filed 7–12–05; 8:45 am] BILLING CODE 4140–01–M BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center on Minority Health and Health Disparities; Notice of Closed Meetings Pursuant to section10(d) of the Federal Advisory Committee Act, as PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the E:\FR\FM\13JYN1.SGM 13JYN1

Agencies

[Federal Register Volume 70, Number 133 (Wednesday, July 13, 2005)]
[Notices]
[Pages 40386-40387]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13813]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Centers of Cancer Nanotechnology Excellence (CCNEs).
    Date: July 19-22, 2005.
    Time: 6 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Holiday Inn Georgetown, 2101 Wisconsin Ave NW., 
Washington, DC 20007.
    Contact Person: Michael B. Small, PhD, Scientific Review 
Administrator, Research Programs Review Branch, Division of 
Extramural Activities, National Cancer Institute, National 
Institutes of Health, 6116 Executive Blvd., Room 8127, Bethesda, MD 
20892-8328, 301-402-0996, smallm@mail.nih.gov.
    This notice is published less than 15 days prior to meeting due 
to scheduling conflicts.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)


[[Page 40387]]


    Dated: July 5, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-13813 Filed 7-12-05; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.